FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio

Lab, Healthcare,,Woman,And,Scientist,With,Tablet,In,Lab,For,Microscope

The U.S. Food and Drug Administration approved on Monday Apellis Pharmaceuticals, Inc.’s (NASDAQ:APLS) Empaveli (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria.

C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the U.S.